SIRPA and neoplasm: The A2+/NY+ tumor cell lines Me275, A375, and Saos-2 express CD47 (Supplemental Figure 2B, top), and we observed higher binding (Supplemental Figure 2B, bottom) as well as saturation of binding at lower concentrations (Supplemental Figure 2C) for CV1-SiRPα-Fc (CV1-Fc) than wtSiRPα-Fc recombinant fusion proteins.